Table 1.

$\mathit{P}{\mathit{a}}_{\mathit{C}\mathit{O}}{}_{{}_{\mathit{2}}}$, $\mathit{P}{\mathit{a}}_{\mathit{O}}{}_{{}_{\mathit{2}}}$, MAP, temperature, and pH during baseline and 90 min of experimental groups

Experimental Groups	$\mathrm{P}{\mathrm{a}}_{\mathrm{C}\mathrm{O}}{}_{{}_{\mathrm{2}}}$, mmHg	$\mathrm{P}{\mathrm{a}}_{\mathrm{O}}{}_{{}_{\mathrm{2}}}$, mmHg	MAP, mmHg	Temperature, °C	pH
MEK/ERK + BDNF
Baseline	45.3 ± 2.1	310.0 ± 21.0	94.6 ± 7.5	36.8 ± 0.1	7.4 ± 0
90 min	45.9 ± 2.7	293.1 ± 17.8	84.7.0 ± 7.3	37.1 ± 0.2	7.4 ± 0
MEK/ERK + aCSF
Baseline	47.0 ± 1.7	317.1 ± 11.8	101.3 ± 0.6	37.1 ± 0.2	7.4 ± 0
90 min	47.5 ± 1.7	276.5 ± 25.9	91.2 ± 8.0	37.2 ± 0.2	7.4 ± 0
PI3K/Akt + BDNF
Baseline	47.3 ± 1.9	331.8 ± 18.6	89.9 ± 6.2	37.1 ± 0.1	7.4 ± 0
90 min	47.5 ± 1.5	289.0 ± 42.2	76.9 ± 6.5	37.2 ± 0.2	7.4 ± 0
PI3K/Akt + aCSF
Baseline	49.5 ± 1.6	308.5 ± 24.2	114.9 ± 2.1	37.1 ± 0.2	7.4 ± 0
90 min	49.5 ± 1.7	283.2 ± 36.0	97.1 ± 1.4	37.2 ± 0.1	7.4 ± 0
PKCθ + BDNF
Baseline	44.5 ± 0.7	328.5 ± 3.5	104.2 ± 5.0	36.9 ± 0.1	7.4 ± 0
90 min	44.6 ± 1.4	317.5 ± 2.9	99.6 ± 7.0	37.1 ± 0.1	7.4 ± 0
PKCθ + aCSF
Baseline	43.6 ± 0.9	323.25 ± 4.7	109.6 ± 6.4	37.5 ± 0.1	7.4 ± 0
90 min	42.7 ± 0.9	303.0 ± 11.4	92.8 ± 5.7	37.1 ± 0.1	7.4 ± 0
Vehicle + BDNF
Baseline	45.5 ± 0.6	317.5 ± 8.3	96.9 ± 3.5	37.1 ± 0.1	7.4 ± 0
90 min	44.9 ± 0.8	293.1 ± 13.5	88.7 ± 10.9	37.3 ± 0.1	7.4 ± 0
Vehicle + aCSF
Baseline	45.5 ± 3.9	294.7 ± 39.8	100.4 ± 6.1	37.2 ± 0.2	7.4 ± 0
90 min	44.8 ± 3.6	295.2 ± 33.3	88.7 ± 10.9	37.1 ± 0.2	7.4 ± 0

Values are expressed as means ± SE. Animals were treated with MEK/ERK inhibitor (U0126), PI3K/Akt inhibitor (PI-828), PKCθ inhibitor (TIP), or inhibitor vehicle [20% DMSO-80% saline (U0126 and PI-828) or 100% aCSF (TIP)]. The animals were administered BDNF or aCSF (BDNF vehicle) after inhibitor or after inhibitor vehicle administration. MAP, mean arterial pressure. There were no significant differences in any group at baseline vs. 90 min.